Alicia Alpuente
Overview
Explore the profile of Alicia Alpuente including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elosua-Bayes I, Alpuente A, Melgarejo L, Caronna E, Torres-Ferrus M, Pozo-Rosich P
Cephalalgia
. 2024 Sep;
44(9):3331024241273966.
PMID: 39314064
Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine prevention but pose safety concerns in pregnancy. We assess the safety of CGRP-mAbs in the periconceptional period...
2.
Membrilla J, Alpuente A, Gomez-Dabo L, Raul G, Marino E, Diaz-de-Teran J, et al.
Eur J Neurol
. 2024 Sep;
31(12):e16484.
PMID: 39287050
Background And Purpose: Patients presenting at the emergency room (ER) with headache often encounter a hostile atmosphere and experience delays in diagnosis and treatment. The aim of this study was...
3.
Casas-Limon J, Quintas S, Lopez-Bravo A, Alpuente A, Andres-Lopez A, Castro-Sanchez M, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274435
Migraine-related stigma is a pervasive issue impacting nearly half of chronic migraine patients, with significant consequences for their quality of life, disability and mental health. Despite its profound effects, migraine...
4.
Pozo-Rosich P, Alpuente A, Silberstein S, Burstein R
Nat Rev Neurol
. 2024 Aug;
20(9):555-568.
PMID: 39160284
OnabotulinumtoxinA (BTX-A) was first linked to beneficial effects in migraine 25 years ago and was approved by the FDA for preventive treatment of chronic migraine in 2010. The treatment has...
5.
Navarro-Perez M, Gonzalez-Quintanilla V, Munoz-Vendrell A, Madrigal E, Alpuente A, Latorre G, et al.
Front Neurol
. 2024 Jun;
15:1417831.
PMID: 38938776
Background: Real-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine...
6.
Gomez-Dabo L, Caronna E, Mas-de-Les-Valls R, Gallardo V, Alpuente A, Torres-Ferrus M, et al.
Toxins (Basel)
. 2024 May;
16(5).
PMID: 38787073
Chronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature...
7.
Caronna E, Gallardo V, Egeo G, Vazquez M, Castellanos C, Membrilla J, et al.
J Neurol Neurosurg Psychiatry
. 2024 May;
95(10):927-937.
PMID: 38777579
Background: Anti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and available treatments for migraine prevention. Patients do not respond alike and many countries have reimbursement policies, which hinder treatments to those...
8.
Alpuente A, Gallardo V, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P
J Headache Pain
. 2024 Apr;
25(1):58.
PMID: 38637736
Background: Migraine is a complex neurological disorder with significant heterogeneity in its clinical presentation and molecular mechanisms. Calcitonin gene-related peptide (CGRP) has emerged as a key player in migraine pathophysiology,...
9.
Alpuente A, Torres-Ferrus M, Caronna E, Pozo-Rosich P
Curr Opin Neurol
. 2024 Mar;
37(3):271-282.
PMID: 38529698
Purpose Of Review: This review aims to explore the use of patient-reported outcome measures (PROMs) in migraine. Traditionally assessed through specific features, recent adoption of PROMs allows for a more...
10.
Ikumi N, Marti-Marca A, Torre-Sune A, Cerda-Company X, Vila-Ballo A, Gallardo V, et al.
Cephalalgia
. 2024 Feb;
44(2):3331024241230279.
PMID: 38416486
Background: To date, a number of studies on migraine have cross-sectionally evaluated sensory sensitivity with aversion thresholds/scores along the migraine cycle, reporting a decreased tolerance to sensory stimuli in different...